• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Medtech stories we missed: Feb. 3, 2017

February 3, 2017 By Chris Newmarker

flashlight MassDevice stories missed
[Image courtesy of Dino Reichmuth on Unsplash]
From disappointing Getinge earnings to a $2.25 billion U.S. Defense Department contract for Cardinal Health to a host of 510(k) clearances, here are seven recent medtech stories that are still worth a mention.

1. Getinge disappoints on earnings—again

Getinge stock took a nearly 10% tumble last week after releasing earnings that Reuters says lagged analyst expectations for the 7th straight quarter. Fourth-quarter sales were up slightly year-over-year, to 9.5 billion Swedish krona (about $1.08 billion), but profits were down nearly 5% to 952 million krona (about $108 million). The Swedish medical device company is still awaiting an FDA action plan for its Hechingen, Germany plant.

2. Cardinal Health wins $2.25B DoD contract

Cardinal Health has won a nearly $2.25 billion contract to provide brand name and generic medical surgical supplies to the U.S. military. Owens and Minor Distribution is receiving an additional $1.125 billion as part of the U.S. Defense Department contract. The Defense Department says its Medical Surgical Prime Vendor Generation V program received six offers for the contracts, which have a 30-month base with an up-to 5-month implementation period. Surgical supplies will go to the Army, Navy, Air Force, Marines, Coast Guard and federal civilian agencies.

3. Zimmer Biomet wins expanded FDA approval for Gel-One

FDA has approved an expanded 26-week efficacy claim for Zimmer Biomet’s Gel-One cross-linked hyaluronate, a single-injection viscosupplement to treat osteoarthritis-related knee pain. “The expanded efficacy claim not only strengthens our competitive positioning, but reinforces our commitment to alleviating pain and restoring mobility for patients at every stage in the continuum of musculoskeletal care, including conservative and non-surgical options,” David Nolan, a Zimmer Biomet group president, said in a Feb. 1 news release.

Read more on our sister site MassDevice.

[Want to stay more on top of MDO content? Subscribe to our weekly e-newsletter.]

Filed Under: Business/Financial News, Featured, Food & Drug Administration (FDA), mHealth (Mobile Health) Tagged With: Biogen, Biolase, Bioverativ, Cambridge Cognition Holdings, Cardinal Health, Getinge, medtech, Precision Spine, U.S. Department of Defese, Zimmer Biomet

IN CASE YOU MISSED IT

  • Abbott will spend $450M to up FreeStyle Libre production in Ireland
  • Better Therapeutics Q2 beats Street as it prepares to submit diabetes therapy for FDA review
  • Study backs Fluidx embolic device for vessel filling
  • Senseonics stock is up as it sticks by revenue guidance
  • Rapid Dose closes first tranche of $5M financing

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS